We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Quality of Life for Subjects Receiving Androgen Deprivation Therapy and Have a Doubling in PSA of Either Less Than or Greater Than 1 Year

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2009 by Urology South Shore Research Inc..
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00703768
First Posted: June 23, 2008
Last Update Posted: February 17, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
AstraZeneca
Information provided by:
Urology South Shore Research Inc.
  Purpose
The purpose of this study is to evaluate if there is a difference in quality of life (as measured by FACT-P) in patients treated with androgen deprivation therapy (ADT) for biochemical failure (PSA recurrence) following surgery or radiation for prostate cancer depending on when ADT is initiated.

Condition
Prostate Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: An Open-Label, Phase ll Trial Comparing FACT-P Scores For Subjects Who Are Indicated To Receive Androgen Deprivation Therapy And Have A Doubling In PSA Post Curative Therapy Of Either Less Than Or Greater Than One Year

Resource links provided by NLM:


Further study details as provided by Urology South Shore Research Inc.:

Primary Outcome Measures:
  • Significant difference in FACT-P scores after 12 months between the 2 groups [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • PSA response [ Time Frame: 12 months ]
  • To evaluate the ease of use of FACT-P to measure Quality of Life [ Time Frame: 12 months ]
  • QOL, side effect profile and evaluate the safety and tolerability of Androgen Deprivation Therapy [ Time Frame: 12 months ]

Estimated Enrollment: 300
Study Start Date: June 2006
Estimated Study Completion Date: July 2010
Estimated Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
A
Patients who have been identified as having a doubling in PSA from nadir of greater than one year
B
Patients who have been identified as having a doubling in PSA from nadir of less than one year.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Male subjects aged 18 years or older with histologically-confirmed prostate cancer, showing biochemical failure (defined as a rising PSA) following definitive therapy (surgery or radiation) and indicated to receive hormone therapy.
Criteria

Inclusion Criteria:

  • 18 years or older
  • Received therapy of curative intent (surgery or radiotherapy)
  • Have a rising PSA which has doubled from a nadir value.
  • Histologically proven prostate cancer requiring androgen deprivation therapy for at least 12 months
  • Written informed consent to participate in the trial.

Exclusion Criteria:

  • Known hypersensitivity to Zoladex, Casodex, ar any component of these products
  • Prior treatment with LHRH agonist or anti-androgens in the past 12 months
  • Any concomitant condition that would make it undesirable, in the physician's opinion, for the subject to participate in the trial or would jeopardize compliance with the protocol.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00703768


Contacts
Contact: Lorne Aaron 450-671-2945 ussr@bellnet.ca
Contact: Carol Paris 450-671-2945 ussr@bellnet.ca

Locations
Canada, Quebec
Urology South Shore Research Inc. Recruiting
Greenfield Park, Quebec, Canada, J4V 2H3
Contact: Lorne Aaron, MD    450-671-2945    ussr@bellnet.ca   
Contact: Carol Paris    450-671-2945    ussr@bellnet.ca   
Principal Investigator: Lorne Aaron, MD         
Sponsors and Collaborators
Urology South Shore Research Inc.
AstraZeneca
Investigators
Principal Investigator: Lorne Aaron, MD
  More Information

Responsible Party: Dr. Lorne Aaron, Urology South Shore Research Inc.
ClinicalTrials.gov Identifier: NCT00703768     History of Changes
Other Study ID Numbers: D8664L00006
First Submitted: June 19, 2008
First Posted: June 23, 2008
Last Update Posted: February 17, 2009
Last Verified: February 2009

Keywords provided by Urology South Shore Research Inc.:
Quality of Life
Androgen Deprivation Therapy
Goserelin

Additional relevant MeSH terms:
Androgens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs